Gaining HTA Reimbursement Approval for Immuno-Oncology Drugs
Today, checkpoint inhibitor immuno-oncology (I-O) treatments are all the rage! Unlike traditional chemotherapies, I-O drugs enable a patient’s own immune system to identify and attack foreign cancer cells while leaving normal cells to continue to function unharmed. This is a huge opportunity to beef up cancer killing while maintaining the integrity of a patient’s quality…
